A lipid metabolism-related gene signature predicts prognosis after tamoxifen treatment in ER + breast cancer and reflects tumor microenvironment heterogeneity through single-cell analysis.

Journal: BMC medical genomics
Published Date: Jul 31, 2025

Abstract

BACKGROUND: Although the clinical outcome of ER + breast cancer patients receiving tamoxifen after surgery is favorable, a proportion of patients experience recurrence or death due to disease progression.

Authors

  • Linxiaoxi Ma
    Department of Breast Surgery, Department of Oncology, Fudan University Shanghai Cancer CenterandKey Laboratory of Breast Cancer in ShanghaiShanghai Medical College, Fudan University, Shanghai, China.
  • Bei Qian
    Department of Thyroid and Breast Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
  • Chen Peng
    Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
  • Gang Liu
    Department of Interventional Radiology, Qinghai Red Cross Hospital, Xining, Qinghai, China.
  • Hao Shen

Keywords

External Resources

Popular Topics
Recent Journals